MAIA MAIA Biotechnology, Inc.

NEUTRAL Impact: 5/10 PRESS-RELEASE
Horizon weeks Filed Mar 4, 2026 Processed 3mo ago Wire GlobeNewswire
Press release: offering
Final — all horizons settled through T+60d
MAIA ▼ -15.03% at T+60d
NEUTRAL call ✗ call lost -15.03% · α vs SPY -26.33% · entry $1.53 → $1.30
Last close $1.27 (close Jun 8) · -16.99% from $1.53 entry
Entry anchored
Mar 4, 03:59 PM ET
via Databento tick
T+1d
+0.65%
call +0.65% · α +1.97%
$1.54
settled 3mo ago
T+5d
+2.61%
call +2.61% · α +4.85%
$1.57
settled 3mo ago
T+20d
-13.07%
call -13.07% · α -9.28%
$1.33
settled 2mo ago
T+60d
-15.03%
call -15.03% · α -26.33%
$1.30
settled 12d ago

Price Chart

Loading chart...

Executive Summary

MAIA Biotechnology closed an underwritten public offering of 20 million shares at $1.50 per share, raising $30 million in gross proceeds. The company may raise an additional $4.5 million if underwriters exercise their 30-day option to purchase 3 million more shares. Proceeds will fund clinical trials and general corporate purposes.

Key Financial Metrics

Deal Value
$30.0M

Actionable Insight

Monitor for potential share price pressure due to near-term dilution; assess whether the capital raise extends the company's runway meaningfully into key clinical milestones.

Key Facts

  • MAIA raised $30 million in gross proceeds through the sale of 20 million shares at $1.50 per share.
  • Underwriters have a 30-day option to purchase up to an additional 3 million shares.
  • Financing included participation from healthcare-dedicated investors and existing shareholders.
  • Net proceeds will be used for clinical trials, working capital, and general corporate purposes.
  • Offering was conducted under a shelf registration (Form S-3) declared effective in August 2023.

Financial Impact

$30 million gross proceeds, with potential for $4.5 million more; significant dilution expected due to large share issuance

dilutioncashequity

Risk Factors

  • Significant equity dilution for existing shareholders given the large number of new shares issued.
  • No guarantee that clinical programs will advance successfully despite additional funding.

Market Snapshot

Exchange
NYSE

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3249706
11 reports for MAIA
Performance horizon
100% Hit rate 6 of 6 directional calls best @ T+5▲ +14.52%Apr 8, 2026
Filters
Rows
Reports for MAIA — sortable, filterable
Type Now
Jun 3, 2026
6d ago
Press Release
BULLISH ★ 6/10
$1.43 $1.50▲ +4.90%▲ +4.50%$1.27 (−11.19%)
Jun 2, 2026
7d ago
Insider Cluster
BULLISH ★ 5/10
$1.35 $1.43▲ +5.93%▲ +6.62%$1.27 (−5.93%)
May 19, 2026
21d ago
DEFA14A
NEUTRAL ★ 2/10
$1.23 $1.29▲ +4.88%▲ +3.84%$1.27 (+3.25%)
May 14, 2026
26d ago
8-K
MIXED ★ 5/10
$1.26 $1.26· 0.00%▲ +0.06%$1.27 (+0.79%)
Apr 27, 2026
6w ago
DEFA14A
NEUTRAL ★ 2/10
$1.24 $1.25▲ +0.81%▲ +1.29%$1.27 (+2.42%)
Apr 16, 2026
7w ago
8-K
BULLISH ★ 7/10
$1.33 $1.35▲ +1.50%▲ +0.29%$1.27 (−4.51%)
Apr 8, 2026
8w ago
8-K
BULLISH ★ 7/10
$1.24 $1.20▼ −3.23%▼ −3.80%$1.27 (+2.42%)
Apr 7, 2026
9w ago
DEFA14A
NEUTRAL ★ 3/10
$1.20 $1.24▲ +3.33%▲ +0.79%$1.27 (+5.83%)
Mar 4, 2026
13w ago
Press Release
NEUTRAL ★ 5/10
$1.53 $1.54▲ +0.65%▲ +1.97%$1.27 (−16.99%)
Mar 3, 2026
14w ago
Press Release
BEARISH ★ 6/10
$1.51 $1.56▼ −3.31%▼ −2.55%$1.27 (+15.89%)
Showing 10 of 11

US Market Status

Market Closed — Opens in 6h 56m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access